Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Inclusion Criteria:

• Adults at the time of signing the Informed Consent Form (ICF)
• Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
• Diagnosed with T2DM

Exclusion Criteria:

• Diagnosed with other types of diabetes than T2DM
• History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
• Uncontrolled severe complications of diabetes